March 20th Options Now Available For NICE

NICE Ltd is presented as an options trade idea at the current stock price of $113.67: a $100 put bid $1.15 would set an effective purchase basis of $98.85 and is estimated to have a 79% probability of expiring worthless, representing a 1.15% one-period return (6.56% annualized YieldBoost). Alternatively, a covered call at the $115 strike with a $6.20 bid would produce a 6.62% total return if called at the March 20 expiry (premium = 5.45% boost, 31.13% annualized); implied volatilities are ~45% (put) and 43% (call) versus a trailing 12-month volatility of 43%.

Analysis

Market structure: Short-dated option sellers and yield-focused accounts are the direct beneficiaries — the $100 put (premium $1.15) and $115 call (premium $6.20) create attractive short-term yields vs buying stock at $113.67. Buyers of large upside in NICE are the losers if covered calls are widely sold because upside will be capped near $115; market makers and prime brokers benefit from flow and hedging fees. Given IV (~43–45%) ~ realized vol (43%), supply/demand for volatility is balanced today but skew toward put selling suggests demand for synthetic yield rather than directional conviction.

Risk assessment: Tail risks include an earnings miss or major contract loss that gaps NICE below $100 (loss amplification for naked put sellers), data/privacy or regulatory actions affecting enterprise licensing, and a macro risk spike that lifts IV >60% causing mark-to-market losses for option writers. Immediate horizon: positioning matters through March 20 expiry (~2 months); short-term catalysts (earnings, guidance, large deal announcements) can flip odds quickly; long-term price depends on fundamentals and subscription retention. Hidden dependencies: dealer delta-hedging can accentuate moves, and concentrated option open interest near $115/$100 could create pinning or violent gamma around expiry.

Trade implications: For yield-biased strategies, sell-to-open the Mar20 $100 put to target acquisition at $98.85 (collect 1.15%, annualized ~6.6%) sized to 1–3% portfolio exposure and defined stop if stock trades <90 or IV >60%. If long stock, sell the Mar20 $115 call to pocket 6.62% to expiry but accept capped upside; prefer collars or protective puts if you need downside protection. For risk-defined exposure prefer 100/95 bull-put spreads (cap max loss = width − credit) or buy a March call spread for directional exposure instead of naked long shares.

Contrarian angles: The market may be underestimating assignment cold-start risk — a 21% implied assignment chance (100%−79%) is non-trivial and concentrates shares into short-put sellers if a draw occurs. The headline annualized YieldBoosts (31% for covered calls) are misleading short-term metrics; don’t equate them with durable returns. Historically, when IV ≈ realized vol ahead of earnings, option selling performs well absent negative surprises — but that flips fast on bad news, so size and defined risk are critical.

Key Decisions for Investors

• Sell-to-open 1x NICE Mar20 $100 put (collect $1.15) sized so that max assignment results in ≤3% portfolio exposure; target acquisition cost $98.85; close or roll if NICE < $90 or IV rises above 60% (both triggers within ~0–8 weeks).
• If already long NICE at ≈$113.67, sell-to-open Mar20 $115 covered call to realize a 6.62% return to expiry; if stock rallies >8% post-sale, buy-to-close before earnings or roll up and out to preserve gains (timeframe: next 0–2 months).
• Use defined-risk alternatives: sell the 100/95 bull-put spread instead of naked puts (max loss = $5 − credit); position size to limit capital at risk to ≤2% of portfolio and target a return-on-risk ≥15% over the ~2-month trade.
• Establish a small (1–2% net exposure) pair trade: long NICE vs short IGV (iShares S&P North American Technology-Software ETF) to isolate idiosyncratic upside for 3–6 months; unwind if NICE underperforms IGV by >10% or after the next earnings release.